Actavia Life Sciences, Inc. (RASP)
Develops drugs to treat acute myeloid leukemia and other blood cancers.
$0.00+0.00%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-87.5%
The outlook
RASP trades at the very bottom of its 52-week range, sitting just 3% above its low. The stock shows mixed price momentum against its moving averages, and analyst sentiment leans bearish overall. Coverage appears sparse, with the StockGlow score reflecting weak sentiment at 22/100.
What’s behind the score
Price trendMixed vs its moving averages
52-week range3% of the way from its 52-week low to high
Market cap
$385,905
52-wk high
$0.00
52-wk low
$0.00
50-day avg
$0.00
200-day avg
$0.00
Trailing P/E
—